Skip to content

TRIAGE: TRIage of Sepsis At emerGency dEpartment

TRIAGE: TRIage of Sepsis At emerGency dEpartment

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02739152
Acronym
TRIAGE
Enrollment
602
Registered
2016-04-15
Start date
2015-04-30
Completion date
2018-03-31
Last updated
2018-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis, Severe Sepsis

Keywords

Sepsis, Severe sepsis, Infections, Worsening

Brief summary

Sepsis is a serious systemic disease defined as a combination of Systemic Inflammation Response Syndrome (SIRS) plus a confirmed or suspected infection. Untreated or inadequately treated cases can lead to severe sepsis or septic shock; being characterized by high mortality and morbidity. Symptoms and signs of sepsis are variable and this makes clinical recognition and assessment very difficult in particular on Emergency Department (ED) patients due to their infectious illness background and the frequent comorbidities. Also, the severity of the condition may not be apparent at initial contact with ED personnel: patients may arrive at ED with mild clinical manifestation and rapidly progress to critical illness, or rather at the opposite others have benign evolution despite a similar symptoms. In these conditions, the main challenge of ED clinicians is differentiating mild infections from life-threatening ones in the heavy workload of ED environment Objective of TRIAGE project is to identify and validate biomarkers able to predict the clinical worsening of patients freshly admitted at Emergency Department. Targeted population is adult patients freshly admitted at ED, whom blood samples will serve to validate candidate markers.

Interventions

None listed

Sponsors

Centre Investigation Clinique, Limoges
CollaboratorUNKNOWN
BioMérieux
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Male or female aged over 18 years * Patient with a single acute infection site suspected or confirmed by the clinician on clinical or paraclinical manifestations. * Patient admitted to ED with at least two systemic inflammatory response syndrome (SIRS) criteria * Patient with symptoms for less than 72 hours upon arrival to the emergency department. * Patient requiring according to physician judgment of hospitalization for at least 48 hours for his septic episode * Patient having been informed of the conditions of the study and having signed the informed consent form

Exclusion criteria

* Patient arrived in an emergency room for over 6 hours. * Patient with septic shock upon arrival to the ED Patient with acute organ failure on arrival at emergencies other than septic. * Patient hospitalized in the week before inclusion. * Patient immunocompromised (HIV, transplanted, patients undergoing chemotherapy, patients receiving treatment\> 20 mg / day of prednisolone or equivalent). * Patient with known pathology among non-infectious pathologies potentially associated with SIRS * Patient diagnosed with sepsis within 30 days before the date of inclusion. * Patient has already been included in the study. * Minor Person. * Person refusing to sign the written consent form. * Pregnant woman parturient or nursing. * Patient with no social security insurance, with restricted liberty or under legal protection

Design outcomes

Primary

MeasureTime frameDescription
patient worsening within a time frame of 72h,change, from day of inclusion, in Sequential Organ Failure Assessment score (SOFA) and/or sepsis classificationUp to 72 hours after admissionA biostatistics analysis will be led in two steps. The first analysis or train set will be conducted on the first 150 patients enrolled, estimated size to reach statistical performance. The objective is to identify markers associated with clinical worsening of patients and decide on a model by selecting the best combination of markers. In a second time, performance will be confirmed during the test set. The number of samples to be tested depends on the target performance calculated with the area under the Receiver operating characteristic (ROC) curve (AUC). We decided to aim for an AUC of 0.75, based on the performance described in the literature for some triage score as MEDS (Mortality in Emergency Department Sepsis) or those associated with Lactate concentration used as marker of sepsis deterioration in ED

Secondary

MeasureTime frameDescription
patient status at D28 (alive or death)Up to 28 days after admissionA biostatistics analysis will be led in two steps. The first analysis or train set will be conducted on the first 150 patients enrolled. The objective is to identify markers associated with mortality at day 28. In a second time, the performance will be confirmed during the test set.

Countries

Belgium, France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026